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The incidence of tuberculosis (TB) remains high 
in much of the developing world, where infectious 
diseases including HIV still represent major 
challenges to healthcare systems.[1,2] Previous studies 
have shown that approximately 1.5% of adults being 
treated for active TB in academic hospitals develop respiratory failure 
requiring admission to an intensive care unit (ICU).[3]
The mortality rate of patients with acute respiratory failure due to TB 
is higher than that of patients with respiratory failure due to other causes, 
and ranges from 40% to 80%.[2,4-6] There is still a paucity of data on the 
determinants of mortality from TB in the ICU. Recent evidence suggests 
that the Acute Physiology and Chronic Health Evaluation II (APACHE 
II) score is predictive of patient mortality.[2] The APACHE II score needs 
to be performed after 24 hours of ICU admission, however, and is not 
validated as a severity-of-illness score in an emergency setting.[7]
The aim of this study was to develop and retrospectively validate a simple 
severity-of-illness score for use in patients with TB requiring ICU admission.
Methods
Study design and population 
We used data from a previously published study in which all patients 
with TB admitted to the medical ICU of Tygerberg Academic 
Hospital, Cape Town, South Africa (SA), from January 2012 to 
May 2013 were prospectively enrolled in order to identify potential 
parameters of poor outcome.[2] A simple severity-of-illness score, 
based on our published dataset as well as other known poor 
prognostic factors, was subsequently retrospectively applied to the 
study population’s admission data in order to assess its validity.
Tygerberg Academic Hospital, a 1 380-bed facility, is one of two 
referral centres in Cape Town and renders a tertiary service to a 
population of about 1.5 million. The study was approved by the 
Stellenbosch University Health Research Ethics Committee.
Patients were considered to have active TB if at least two of the 
following criteria were met: (i) smear positive for acid-fast bacilli (AFB) 
or GeneXpert MTB/RIF (Cepheid, SA) on sputum, tracheal aspirate 
or any other clinical specimen; (ii) culture positive for Mycobacterium 
tuberculosis (MTb) on sputum, tracheal aspirate or any other clinical 
specimen; (iii) histopathological identification of TB granuloma on 
biopsied tissues; (iv) strong clinical suspicion of active TB; (v) strong 
radiological evidence of active TB; or (vi) pleural fluid with a lymphocyte 
predominance (>75% lymphocytes and/or lymphocyte/neutrophil ratio 
>0.75) with an adenosine deaminase level >40 IU/L. A strong clinical 
suspicion of active TB required at least two of four constitutional 
symptoms (loss of weight with accompanying fever, night sweats, 
productive cough, loss of appetite for >2 weeks) as well as known TB 
contact or a history of previous pulmonary TB. Positive cultures were 
identified as MTb and tested for susceptibility to rifampicin and isoniazid 
using the MTBDRplus line probe assay (Hain LifeSciences, Germany).
Clinical data, laboratory, imaging and related 
investigations
Patient demographics, comorbid diseases (including HIV infection, 
AIDS, chronic obstructive pulmonary disease (COPD) and diabetes) 
and relevant medication use were documented.
Laboratory investigations collected included white cell count, 
platelet count, serum haemoglobin, serum albumin, C-reactive 
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protein, creatinine, alanine aminotransferase (ALT) and serum 
glucose. Absolute CD4 counts were measured in all HIV-positive 
patients. All admission chest radiographs were reviewed by two 
pulmonologists blinded to the clinical data and classified as follows: 
(i) cavitation; (ii) miliary or diffuse interstitial infiltrates; (iii) lobar 
consolidation; (iv) pleural effusion; (v) isolated lymphadenopathy; 
or (vi) normal. The APACHE II score was calculated for all patients 
during the first 24 hours of the ICU stay.[7]
Management, course and complications 
All patients were managed according to local guidelines and received 
maximal supportive therapy.[2,8] The standard combination anti-
TB treatment regimen was used unless significant renal or hepatic 
impairment or confirmed drug resistance was present.[8] Standard 
diagnostic criteria for the diagnosis of shock, renal failure, multiorgan 
dysfunction syndrome (MODS) and acute respiratory distress 
syndrome (ARDS) were used, as defined by accepted international 
criteria.[9-11] Patients were categorised as either ICU/hospital survivors 
or non-survivors.
Statistical aspects and development of the severity-of-
illness score
Descriptive statistics and χ2 or Fisher’s exact tests (where indicated) 
were performed on dichotomous categorical variables, and t-tests on 
continuous data. A scoring system was generated by identifying the 
four most significant and clinically unrelated parameters identified 
from the prospective data collection and combining these with two 
known predictors of poor outcome: septic shock and a low arterial 
partial pressure of oxygen/fractional inspired oxygen (P:F) ratio.[9,11] 
For simplicity, we decided not to generate a weighted scoring system.
Results
Study population characteristics
Over the study period, 83 patients with TB (mean (standard deviation 
(SD)) age 36.5 (12.9) years, 38 males, 44 HIV-positive) were admitted 
to the medical ICU. The majority of the patients (n=69, 83.1%) 
had active pulmonary TB; 14 patients had exclusive evidence of 
extrapulmonary TB and 23 had both pulmonary and extrapulmonary 
TB. Extrapulmonary involvement included pleural disease (n=13), 
disseminated disease (n=11), meningitis (n=7), abdominal TB (n=4) 
and disease at other sites (n=2). Thirty-two patients (38.6%) were on 
TB treatment at the time of admission.
The mean duration of ICU admission was 11.9 days (range 1 - 56). 
The primary reason for admission was acute respiratory failure in 
two-thirds of patients (n=56). Other reasons included a decreased 
level of consciousness (n=7), surgery of the gastrointestinal tract 
(n=3) and concomitant disease not directly related to TB (n=3).
Tracheal aspirates (TAs) were obtained from all but three patients; 
39.8% were AFB-positive. Mycobacterial cultures obtained from a 
variety of sites, including TAs, were positive in 48 patients (57.8%). 
Other sources included pleural fluid, cerebrospinal fluid (CSF), 
blood, lymph nodes, ascites, urine and placenta. The diagnosis of TB 
in the absence of direct microbiological proof was based on a high 
clinical probability combined with radiological evidence (n=14), 
pleural fluid analysis alone (n=5), CSF analysis (n=7) or histological 
findings (n=1). Only two patients had isoniazid monoresistance; 
none had multidrug-resistant TB (MDR-TB).
In total, 45 of 83 patients survived ICU admission (ICU mortality 
45.8%) and 34 survived to hospital discharge (in-hospital mortality 
59.0%). Three patients who were readmitted all survived their 
respective ICU and hospital admissions.
Predictors of mortality
The clinical, radiological and laboratory data of ICU survivors and 
non-survivors are summarised in Tables 1 - 3. Of the 31 patients with 
HIV co-infection and a CD4 count <200 cells/µL, 16 did not survive 
the ICU (OR 5.87; 95% CI 1.11 - 30.95; p=0.04).
Renal failure was present in 31 patients. Of these, 24 did not 
survive hospital admission (OR 3.70; 95% CI 1.15 - 10.09; p=0.02).
Neither ARDS (n=26, 35.6%) nor MODS (n=25, 30.1%) was 
associated with increased mortality. The ICU course was complicated 
by the development of ventilator-associated pneumonia in 19 patients 
(27.7%), which did not adversely influence outcome.
Suggested severity-of-illness score 
We combined septic shock and a low P:F ratio with the following 
four parameters identified as potentially significant in our study 
cohort: (i) HIV with CD4 count <200 µL; (ii) renal failure; (iii) diffuse 
parenchymal infiltrates/miliary pattern on the chest radiograph; 
and (iv) absence of TB treatment on admission. We subsequently 
Table 1. Clinical data, ICU survivors v. non-survivors 
All (N=83) Survivors (N=45) Non-survivors (N=38) OR (95%CI) p-value 
Gender (female), n 45 25 20 0.89 (0.37 - 2.11) 1
Age (years), mean (SD) 36.5 (12.9) 35.2 (11.6) 37.3 (13.8) N/A 0.80
APACHE II, mean (SD) 20.7 (8.3) 19.3 (7.7) 22.4 (8.8) N/A 0.09
Pulmonary TB, n 69 36 33 1.65 (0.58 - 6.10) 0.59
Isolated pulmonary TB, n 46 23 23 1.47 (0.61 - 3.52) 0.52
Extrapulmonary TB, n 37 22 15 0.68 (0.28 - 1.63) 0.26
Isolated extrapulmonary TB, n 14 9 5 0.61 (0.18 - 1.99) 0.56
HIV-positive, n 44 26 18 0.66 (0.28 - 1.57) 0.47
HIV with CD4 <200, n 31/44 15/26 16/18 5.87 (1.11 - 30.95) 0.04
AIDS, n 27 13 14 1.46 (0.57 - 3.61) 0.59
Diabetes mellitus, n 9 5 4 0.94 (0.23-3.79) 1
COPD, n 6 2 4 2.52 (0.44 - 14.64) 0.41
TB treatment on admission, n 32 22 10 0.37 (0.15 - 0.95) 0.06
N/A = not applicable.
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proposed the following scoring system, designated ‘SCCOR-TB’, 
with one point for each of the parameters: (i) septic shock; (ii) HIV 
with CD4 <200/µL; (iii) creatinine >140 µmol/L (male) or >120 
µmol/L (female); (iv) P:F O2 ratio <200; (v) chest radiograph showing 
diffuse parenchymal infiltrates/miliary pattern; and (vi) absence of 
TB treatment on admission. The scoring system was subsequently 
retrospectively applied to the study population’s admission data.
Mortality rates according to the suggested  
severity-of-illness score
Severity-of-illness scores (Table 4) were significantly lower in 
survivors than in non-survivors (mean (SD) 2.27 (1.47) v. 3.58 (1.08); 
p<0.01). Moreover, a score of ≥2 was associated with a significantly 
higher mortality than a score of <2 (7.1% v. 46.4%; OR 15.03; 95% 
CI 1.86 - 121.32; p<0.01). Likewise, a score of ≥3 was associated with 
a significantly higher mortality than a score of <3 (64.6% v. 20.0%; 
OR 7.29; 95% CI 2.64 - 20.18; p<0.01).
Discussion
We found the mortality rate among patients admitted to the ICU with 
TB to be extremely high: approximately 46% did not survive the ICU 
admission, and 59% died in hospital. Although only a few clinical 
parameters, special investigations or other ancillary tests predicted 
outcome, we were able to retrospectively validate a simple six-
point scoring system based on septic shock, HIV with CD4 counts, 
creatinine values, P:F ratios, chest radiography and TB treatment 
on admission. Severity-of-illness scores were significantly lower in 
survivors than non-survivors. Almost 1/2 patients with a score of ≥2 
did not survive (v. <1/10 with a score of <2; p<0.01), whereas 2/3 
patients with a score of ≥3 died (v. 1/5 with a score of <3; p<0.01).
Our mean APACHE II score of 20.7 predicted a mortality rate of 
30 - 40%,[7] suggesting that this globally used score underestimates 
mortality in this population. Moreover, it is only calculated after 24 
hours of admission, making it an impractical initial severity-of-illness 
score for use in patients with TB requiring ICU admission. Simple 
severity-of-illness scores have been shown to be accurate in predicting 
a poor outcome in other severe illnesses, e.g. the Severity-of-Illness 
Score for Toxic Epidermal Necrolysis (SCORTEN), which was recently 
validated at our institution.[12] Our data suggest that SCCOR-TB cut-
offs of both ≥2 and ≥3 were associated with significant increments 
in mortality, which could potentially guide clinicians in identifying 
patients at a significantly increased risk of dying from TB in the ICU.
Table 2. Radiological findings, ICU survivors v. non-survivors 
Parameter All (N=83), n Survivors (N=45), n Non-survivors (N=38), n OR (95%CI) p-value 
Cavitation 12 10 2 0.19 (0.04 - 0.95) 0.03
Miliary and diffuse interstitial 47 14 33 14.61 (4.71 - 45.36) <0.01
Lobar consolidation 16 15 1 0.05 (0.01 - 0.43) <0.01
Pleural effusion 13 9 4 0.47 (0.13 - 1.67) 0.38
Lymph node enlargement alone 1 1 0 N/A N/A
Normal 1 1 0 N/A N/A
N/A = not applicable.







Mean (SD) p-value 
CD4 count (cells/µL) 600 - 1 500 160.2 (163.6) 198.5 (180.7) 104.8 (119.1) 0.06
P:F ratio >300 215.2 (113.2) 220.0 (115.5) 209.4 (111.8) 0.67
White cell count (× 109/L) 4.0 - 11.0 13.5 (7.1) 14.1 (6.7) 12.8 (7.6) 0.41
Platelet count (× 109/L) 150 - 400 282.8 (165.7) 307.6 (175.1) 253.4 (150.9) 0.14
Haemoglobin (g/dL) 12.0 - 15.0* 9.76 (2.41) 9.52 (2.55) 10.04 (2.23) 0.26
Serum albumin (g/L) 35 - 50 25.1 (6.3) 25.1 (7.0) 25.1 (5.5) 0.98
C-reactive protein (mg/L) <5 175.2 (94.4) 168.8 (93.3) 183.0 (97.0) 0.53
Creatinine (µmol/L) <90* 137.7 (152.0) 131.6 (139.4) 145.0 (167.4) 0.69
ALT (U/L) 5 - 40 133.8 (305.1) 178.6 (398.8) 84.8 (138.1) 0.21
Serum glucose (mmol/L) 4.4 - 6.1 8.80 (4.76) 8.32 (4.55) 9.35 (5.00) 0.33
*For females.











≤1 14 13 1 7.1
2 21 15 6 28.6
3 18 10 8 44.4
≥4 30 7 23 76.7
<2 14 13 1 7.1
≥2 69 32 37 46.4
<3 35 28 7 20.0
≥3 48 17 31 64.6
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We specifically aimed to identify parameters that could be readily 
assessed at practically all levels of medical care, and used both the 
prospective data set in addition to known poor prognostic factors 
(e.g. septic shock) to develop the score.[9] Although the ORs of the 
various parameters differed, we opted to test our proposed scoring 
system with equally weighted parameters, in line with recent trends 
for simplicity.[13] In an attempt not to ‘double-penalise’ HIV-positive 
patients and use clinically related parameters, we opted to include 
the parameter HIV with a CD4 count <200/µL (OR 5.87), rather 
than AIDS (OR 1.46) or any other AIDS-defining diseases. Active 
TB itself has a significant impact on CD4 cell homeostasis,[14] and 
our data suggest that non-survivors tend to have a lower count (105 
v. 199; p=0.06).
We confirmed the well-known association between the lack of 
radiological evidence of cavitation and increased mortality.[15] More-
over, we found that the presence of miliary and diffuse interstitial 
infiltrates was significantly associated with mortality (OR 14.6; 
p<0.01). The latter parameter was therefore included in the proposed 
scoring system.
Delay in the initiation of anti-TB treatment is known to increase 
mortality.[16] We found that survivors were more likely to be on TB 
treatment on admission than non-survivors (p=0.06), and therefore 
also included this in our scoring system.
Our study has several potential limitations. We avoided suggesting 
a complex weighted scoring system (which would arguably have 
yielded a statistically more accurate system), as we aimed to develop 
a simple severity-of-illness score that can potentially be used at 
practically any level of care in SA. There was not a single case 
of MDR-TB in our cohort, and drug susceptibility was therefore 
not included in the scoring system. Furthermore, a selection bias 
towards healthier patients being referred and admitted to the ICU 
may have been present, given the limited ICU resources in our 
setting.[2] We included a small proportion of cases (14/83) in which 
diagnoses were never microbiologically confirmed (diagnosed 
on clinical and radiological criteria). Although this is not an 
infrequent practice in studies from high endemic areas,[17] it may 
have introduced some bias.
In conclusion, we were able to validate a simple scoring system 
based on six parameters: septic shock, HIV with CD4 counts, 
creatinine values, P:F ratios, chest radiography and TB treatment 
on admission. The proposed scoring system can potentially identify 
patients at an increased risk of dying from TB in the ICU. Further 
prospective studies are indicated to validate its use.
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